This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders On Launch Of Jakafi And Lead Clinical Programs

Stocks in this article: INCY

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi, the acceptance of Jakafi in the marketplace, risks related to market competition, the results of further research and development, risks and uncertainties associated with sales, marketing and distribution requirements, risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, the ability to enroll sufficient numbers of subjects in clinical trials, other market or economic factors and technological advances, unanticipated delays, the ability of Incyte to compete against parties with greater financial or other resources, risks associated with Incyte's dependence on its relationships with its collaboration partners, and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2012.

Incyte disclaims any intent or obligation to update these forward-looking statements.

 

INCYTE CORPORATION

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

   
Three Months Ended Nine Months Ended

September 30,

September 30,

  2012     2011   2012     2011
Revenues:
Product revenues, net $ 43,695 $ - $ 92,700 $ -
Contract revenues 16,737 16,737 90,211 65,211
Other revenues   60   45   302   354
 
Total revenues   60,492   16,782   183,213   65,565
 
Costs and expenses:
Cost of product revenues 31 - 58 -
Research and development 50,079 44,604 150,627 126,830
Selling, general and administrative 20,520 14,282 61,634 37,067
Other expenses   -   -   -   712
 
Total costs and expenses   70,630   58,886   212,319   164,609
 
Loss from operations (10,138) (42,104) (29,106) (99,044)
Interest and other income, net 27 45 393 249
Interest expense   (11,573)   (11,019)   (34,293)   (32,666)
 
Loss before income taxes (21,684) (53,078) (63,006) (131,461)
 
Provision for income taxes   26   -   93   -
 
Net loss $ (21,710) $ (53,078) $ (63,099) $ (131,461)
 
Basic and diluted net loss per share $ (0.17) $ (0.42) $ (0.49) $ (1.05)
 
Shares used in computing basic and diluted net loss per share 130,851 126,260 129,093 125,019
 
 
INCYTE CORPORATION
Condensed Consolidated Balance Sheet Data

(in thousands)

   
September 30, December 31,

2012

2011

 
Cash, cash equivalents, and short-term marketable securities $ 243,599 $ 277,594
Accounts receivable, net 16,540 6,415
Deferred revenue – Product revenues - 2,332
Total assets 296,535 328,962
Convertible senior notes 315,874 298,193
Convertible subordinated notes 18,725 17,960
Total stockholders’ deficit (219,950) (227,077)
 




7 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs